Novartis AG v. Union of India & Others

Supreme Court of India | Decided: 1 April 2013 Citation: (2013) 6 SCC 1

Background

Glivec (generic name: imatinib mesylate, beta crystalline form) is an anti-cancer drug developed by Swiss pharmaceutical giant Novartis AG for the treatment of chronic myeloid leukaemia and certain other cancers. The drug’s commercial and therapeutic importance was significant – it was widely regarded as a breakthrough in targeted cancer therapy – but its high price placed it beyond the reach of most patients in developing countries, including India.

The litigation has its origins in a chain of pharmaceutical development and patent filings spanning several decades. In 1992, Novartis filed a patent application for “imatinib” (the free base compound) in the United States, which also encompassed pharmaceutically acceptable salt forms of imatinib. The US Patent and Trademark Office (USPTO) granted this patent. In 2001, the US Food and Drug Administration approved imatinib mesylate – a salt form of imatinib that is soluble in the human body – for clinical use under the brand name Glivec.

In 1997, Novartis filed a further US patent application for a specific variation of imatinib mesylate, namely its “beta crystalline form,” which enables oral administration of the drug. The USPTO granted a patent on this form as well. In 1998, Novartis sought product patent protection for the beta crystalline form of imatinib mesylate in India. However, India did not permit product patents in pharmaceuticals prior to 2005 (when it amended the Patents Act in compliance with the TRIPS Agreement) and accordingly the application was kept in a “mailbox” pending the legislative changes.

After India amended its patent law in 2005, the application was examined by the Indian Patent Office, which rejected it in 2006. The rejection was based on the finding that Novartis had failed to demonstrate “significantly enhanced efficacy” of the beta crystalline form over imatinib mesylate as required under Section 3(d) of the Patents Act, 1970. The Intellectual Property Appellate Board (IPAB) upheld the rejection on 26 June 2009. Novartis appealed to the Supreme Court of India.

In an attempt to meet the enhanced efficacy requirement, Novartis had in 2005 conducted studies claiming to show approximately 30% increased bioavailability of the beta crystalline form of imatinib mesylate over the original imatinib free base compound.

Issues for Determination

The Supreme Court was called upon to determine:

Whether imatinib mesylate (the salt form) lacked novelty in view of the earlier patent on imatinib (the free base) and whether it was already encompassed within the claims of the prior patent.
Whether the beta crystalline form of imatinib mesylate satisfied the requirement of “significantly enhanced efficacy” under Section 3(d) of the Patents Act, 1970, so as to qualify as a patentable “invention.”
What is the correct interpretation of the term “efficacy” under Section 3(d) – whether it refers to therapeutic efficacy alone or extends to physico-chemical and other non-therapeutic properties.
Whether increased bioavailability of a drug compound constitutes sufficient proof of enhanced therapeutic efficacy for the purposes of Section 3(d).
The broader doctrinal question of whether Section 3(d) operates as a bar to patentability of incremental pharmaceutical innovations generally.

Key Holdings of the Court

On imatinib mesylate, the Court held that the salt form lacked novelty as it was already encompassed within the claims of the original 1992 imatinib patent. The Court relied on scientific literature describing not only the free base imatinib but also its salt forms and their anti-tumoral properties. Crucially, it also applied the principle of claim consistency, noting that Novartis had in European patent infringement proceedings argued that the original imatinib patent covered the mesylate salt – a position inconsistent with its attempt to claim a narrow reading of the same patent in the novelty examination of a derivative.
While the Court accepted that the beta crystalline form of imatinib mesylate was not encompassed by the original imatinib claims (and was therefore potentially novel), it held that the beta crystalline form failed to meet the enhanced efficacy requirement under Section 3(d) and therefore did not constitute a patentable “invention.”
The Court interpreted “efficacy” under Section 3(d) as referring exclusively to therapeutic efficacy. The physico-chemical properties of the beta crystalline form – such as improved flow properties, better thermodynamic stability and lower hygroscopicity – were held to be irrelevant to the efficacy examination because they had no bearing on the drug’s therapeutic effect on the human body.
The Court clarified that increased bioavailability does not automatically translate into enhanced therapeutic efficacy. Since bioavailability only measures the extent to which a drug reaches its site of action, it does not by itself demonstrate what effect the drug produces once it arrives there. Novartis had failed to submit clinical trial data or other evidence establishing that the 30% increase in bioavailability of the beta crystalline form actually produced a greater therapeutic effect on patients.
The Court clarified that its decision did not constitute a general rejection of incremental innovation in the pharmaceutical sector. Increased bioavailability could, in appropriate cases, lead to enhanced therapeutic efficacy – the point was that such a connection must be demonstrated by evidence rather than assumed.
The Court declined to offer an exhaustive definition of “therapeutic efficacy,” leaving open whether it should be construed narrowly (to cover only curative effect) or more broadly (to also include enhanced safety and reduced toxicity).

Doctrinal Significance

The Novartis judgment is one of the most globally significant decisions in the history of patent law, carrying ramifications well beyond India’s borders.

It operationalises Section 3(d) as a potent anti-evergreening tool. By holding that therapeutic efficacy is the relevant standard and that physico-chemical improvements do not satisfy it, the Court established a demanding and specific threshold for pharmaceutical derivative patents. This effectively bars the most common forms of pharmaceutical evergreening – reformulations, polymorph patents, new salt forms – unless genuine therapeutic improvement is demonstrated.

It establishes the principle of claim consistency in Indian patent law. A patentee who interprets its existing patent broadly in infringement litigation cannot later claim the same patent has a narrower scope in novelty proceedings relating to a follow-on application. This principle, drawn from English patent law, was firmly endorsed and applied.

It defines “efficacy” in Section 3(d) as therapeutic efficacy, setting a clear – though not inflexible – standard. The Court explicitly left open the possibility that a broader definition encompassing safety, reduced side effects or reduced toxicity could be appropriate in particular cases, preserving some doctrinal flexibility.

It clarifies the relationship between bioavailability and therapeutic efficacy, holding them to be distinct and not automatically correlated. This is a technically important holding that affects how pharmaceutical patent applicants must frame and support their efficacy claims before the Indian Patent Office.

It affirms TRIPS flexibilities in pharmaceutical patenting. The judgment is globally cited as an authoritative example of a developing country using the flexibility inherent in the TRIPS framework to calibrate its patent law in favour of public health and access to medicines. It became a reference point in international policy debates around pharmaceutical patent reform, compulsory licensing and the Doha Declaration on TRIPS and Public Health.

It has profoundly influenced patent prosecution and litigation strategy in India. Patent applicants in the pharmaceutical sector now routinely address Section 3(d) explicitly in their applications, conducting and submitting comparative therapeutic efficacy studies rather than relying solely on physico-chemical data. The judgment has also shaped the examination guidelines of the Indian Patent Office for pharmaceutical applications.